未经证实:Toll样受体与严重急性呼吸道综合征冠状病毒(SARS-CoV)和中东呼吸道疾病(MERS)的病理生理学有关,根据几项研究。SARS-CoV-2的全基因组测序表明,TLR7基因可能与病毒的发病机理有关,因为该病毒包含可以与TLR7结合的ssRNA模式。
UNASSIGNED:本研究的目的是研究TLR7(rs3853839)C/G多态性的功能和TLR7mRNA转录本在发育过程中的表达,COVID-19的严重程度和进展。
UNASSIGNED:一项病例对照研究包括285名参与者,分为两组:150名以前没有合并症的COVID19中年人和135名健康志愿者作为对照。采用TaqMan检验对TLR7(rs3853839)C/G多态性进行基因分型,并使用实时PCR确定其mRNA转录物的相对表达。使用ELISA法测定血清中IL-6的水平,作为细胞因子风暴和COVID-19严重程度的指标。
未经证实:GG基因型在COVID-19患者中(38.7%)比对照组(4.4%)更为常见,OR为19.86(95%CI:7.85;50.22),与疾病严重程度和不良临床结局(住院,呼吸衰竭,心脏并发症,ICU入院和机械通气)。因此,G等位基因在病例中相当高(57.0%),而C等位基因在对照组中明显更高(p=0.001)。发现GG基因型在严重/严重不适的患者中更为常见。COVID-19患者的TLR7mRNA表达水平(2.44±0.89)明显高于对照组(1.06±0.46)(p=0.001)。TLR7mRNA水平在具有GG基因型的COVID19患者中最高(rs3853839)。GG基因型患者的白细胞计数明显降低,但血清铁蛋白明显升高,CRP,IL-6和D二聚体水平(P分别为0.045、0.001、0.023、0.033、0.001)。
未经证实:TLR7SNP(rs3853839)的GG形式可能是COVID-19感染的遗传风险因素,严重的疾病和不良的临床结果。在严重/严重不适且预后不良的COVID-19患者中,TLR7mRNA表达也升高,表明它们可以用作COVID-19预后生物标志物。
UNASSIGNED: Toll-like receptors are implicated in the pathophysiology of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory disease (MERS), according to several studies. The whole-genome sequencing of SARS-CoV-2 revealed that the TLR7 gene could be implicated in the virus\'s pathogenesis since the virus includes ssRNA patterns that could bind to TLR7.
UNASSIGNED: The purpose of this study was to look into the function of the TLR7 (rs3853839) C/G polymorphism and the expression of TLR7 mRNA transcript in the development, severity and progression of COVID-19.
UNASSIGNED: A case-control study included 285 participants who were divided into two groups: 150 middle-aged people with COVID 19 who had no previous co-morbidities and 135 healthy volunteers who served as controls. TaqMan test was used to genotype the TLR7 (rs3853839) C/G polymorphism, and real-time PCR was used to determine the relative expression of its mRNA transcript. The level of IL-6 in serum was determined using the ELISA method as an indicator of cytokine storm and COVID-19 severity.
UNASSIGNED: The GG genotype was shown to be much more common in COVID-19 patients (38.7%) than controls (4.4%), with an OR of 19.86 (95% CI: 7.85; 50.22) and was linked to disease severity and poor clinical outcomes (hospitalization, respiratory failure, cardiac complications, ICU admission and mechanical ventilation).As a result, the G allele was considerably higher in cases (57.0%), while the C allele was significantly higher in controls (p = 0.001). The GG genotype was found to be substantially more common in patients who were severely/critically unwell. TLR7 mRNA expression levels were significantly higher in COVID-19 patients (2.44 ± 0.89) than in controls (1.06 ± 0.46) (p = 0.001). TLR7 mRNA levels were highest in COVID 19 patients with the GG genotype (rs3853839). Patients with the GG genotype had considerably lower WBC counts, but significantly higher serum ferritin, CRP, IL-6 and D dimer levels (P = 0.045, 0.001, 0.023, 0.033, 0.001, respectively).
UNASSIGNED: The GG form of the TLR7 SNP (rs3853839) could be a genetic risk factor for COVID-19 infection, severe illness and poor clinical outcome. TLR7 mRNA expression was also elevated in COVID-19 patients who were severely/critically unwell and had a bad outcome, suggesting that they could be used as COVID-19 prognostic biomarkers.